Deferred Income Tax Expense (Benefit) of Grace Therapeutics, Inc. from 31 Mar 2021 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Grace Therapeutics, Inc. quarterly and annual Deferred Income Tax Expense (Benefit) in USD history and change rate from 31 Mar 2021 to 30 Jun 2025.
  • Grace Therapeutics, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending 30 Jun 2025 was $0.
  • Grace Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2024 was $3,202,000, a 75% decline from 2023.
  • Grace Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was $1,834,000, a 81% increase from 2022.
  • Grace Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was $9,542,000, a 1373% decline from 2021.
Source SEC data
View on sec.gov
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Change (%)

Grace Therapeutics, Inc. Quarterly Deferred Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $0 +$724,000 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2026 Q1
Q2 2024 $724,000 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2026 Q1

Grace Therapeutics, Inc. Annual Deferred Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $3,202,000 -$1,368,000 -75% 01 Apr 2024 31 Mar 2025 10-K 23 Jun 2025 2025 FY
2023 $1,834,000 +$7,708,000 +81% 01 Apr 2023 31 Mar 2024 10-K 23 Jun 2025 2025 FY
2022 $9,542,000 -$8,894,000 -1373% 01 Apr 2022 31 Mar 2023 10-K 21 Jun 2024 2024 FY
2021 $648,000 -$648,000 01 Apr 2021 31 Mar 2022 10-K 23 Jun 2023 2023 FY
2020 $0 01 Apr 2020 31 Mar 2021 10-K 21 Jun 2022 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.